Spero Therapeutics
Updated: May 22, 2026
CEO Ankit Mahadevia
Country: USA | Funding: $443.6M (+)
Founded: 2013
Website: https://sperotherapeutics.com/
Spero Therapeutics develops medications for patients suffering from rare diseases and multidrug-resistant bacterial infections. Its lead drug, the antibiotic Tebipenem HBr, is an oral carbapenem being developed for the treatment of complicated urinary tract infections, including pyelonephritis. If approved, Tebipenem, which has already successfully completed Phase 3 clinical trials, will be the first oral carbapenem for the treatment of this disease. Carbapenems are an important subclass of antibiotics for the treatment of infections caused by drug-resistant Gram-negative bacteria. Carbapenems have become the standard of care for many infections caused by multidrug-resistant Gram-negative bacteria, but are currently only available as intravenous formulations for this indication.
Founded: 2013
Website: https://sperotherapeutics.com/
Spero Therapeutics develops medications for patients suffering from rare diseases and multidrug-resistant bacterial infections. Its lead drug, the antibiotic Tebipenem HBr, is an oral carbapenem being developed for the treatment of complicated urinary tract infections, including pyelonephritis. If approved, Tebipenem, which has already successfully completed Phase 3 clinical trials, will be the first oral carbapenem for the treatment of this disease. Carbapenems are an important subclass of antibiotics for the treatment of infections caused by drug-resistant Gram-negative bacteria. Carbapenems have become the standard of care for many infections caused by multidrug-resistant Gram-negative bacteria, but are currently only available as intravenous formulations for this indication.
